Pretreatment ¹⁸F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer

Table 1

Patient and tumor characteristics.

Characteristics	Cases (%)
Patients, n	85
Gender
Male	51 (60%)
Female	34 (40%)
Age, years
Mean ± SD	59.27 ± 11.56
Range	26–79
BMI
Mean ± SD	21.97 ± 3.21
Range	15.43–33.87
Tumor location
Left hemicolon	33 (38.9%)
Right hemicolon	22 (25.9%)
Rectum	30 (35.2%)
Histologic type
Nonmucinous adenocarcinoma	83 (97.6%)
Mucinous adenocarcinoma	2 (2.4%)
Differentiation
Well/moderate	74 (87.1%)
Poor	11 (12.9%)
UICC-TNM stage
I/II	33 (38.8%)
III/IV	52 (61.2%)
T-category
Tis, T1, T2	4 (4.7%)
T3, T4	81 (95.3%)
N-category
Positive	67 (78.8%)
Negative	18 (21.2%)
M-category
Positive	56 (65.9%)
Negative	29 (34.1%)
Tumor size, mm
Mean ± SD	49.2 ± 28.17
Range	10–180
Mutational status
KRAS/NRAS/BRAF mutated	46 (54.1%)
Wild-type	39 (45.9%)

UICC, Union for International Cancer Control.